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Available online 29 June 2016Human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) provide a novel assay system to assess
cardiac safety in drug development to overcome a problem of species difference in non-clinical testing during
drug development. Using the multi-electrode array (MEA) platform, electrophysiological activities of iPS-CMs
can be recorded easily to assess QT prolongation and proarrhythmic potential of drug candidates. Here we
have established a standardized protocol to evaluate the possibility of iPS-CMs, and shared the protocol with
an international consortium. To obtain reproducible and reliable experimental data from these cells, we deter-
mined the optimal experimental conditions, such as cell density,MEA coating, culture conditions, high-pass ﬁlter
frequency, deﬁnition of early afterdepolarization or triggered activity, and calibration compounds. Based on the
protocol, our validation study using 60 compounds is in progress. Thus, MEA-based experiments using iPS-CMs
would be a standard testing method to evaluate QT prolongation and proarrhythmic potentials.-ku, 158-8501
. This is an op© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Standardization1. Introduction
Torsade de pointes (TdP) associatedwithQT prolongation is a signif-
icant factor for the high attrition rate of new-drug candidates in clinical
studies and withdrawal of products from the market. Since the QT pro-
longation potential is a surrogate marker of TdP, drug candidates are
evaluated non-clinically by in vitro hERG assays and in vivo QT assays
(ICH S7B guideline) and clinically by tQT/QTc study (ICH E14 guideline)
(Anonymous, 2005a; Anonymous, 2005b; Chi, 2013; Sager, Gintant,
Turner, Pettit, and Stockbridge, 2014). While there have been no with-
drawals by TdP from the market, after the implementation of S7B and
E14 guidelines, drug-induced proarrhythmia has still been amajor safe-
ty concern in the development of new drugs (Redfern et al., 2003;
Lacerda et al., 2008; Gintant, 2011). Thus, we need a new paradigm
for non-clinical test methods to predict the proarrhythmic risk of the
drugs. Human iPS cell-derived cardiomyocytes (iPS-CMs)might be use-
ful to establish the new paradigm, because of their expression of multi-
ple ion channels (Ma et al., 2011).
To realize the new paradigm, we ﬁrst performed survey regarding
for availability of iPS-CMs. We found that there were inter-laboratory
variations in experimental conditions such as iPS cell lines,, Japan.
en access article underdifferentiation methods, types of experimental preparation, culture
conditions, testing methods for cell function, drugs, and endpoints
(Tanaka et al., 2009; Zhang et al., 2009; Itzhaki et al., 2011; Mehta et
al., 2011; Harris et al., 2013; Ohno et al., 2013). Thus, it was difﬁcult to
evaluate reproducibility and reliability of results using iPS-CMs. For
the robustness of pharmacological and toxicological testing methods
using iPS-CMs, we need a standardized protocol using the same cell
preparations, measurement method, positive and negative compounds,
and have to decide endpoints to predict the proarrhythmic risk.
In thismanuscript, wewill review our activities for the development
of a standardized protocol using iPS-CMs for safety assessment toward
international acceptance.
2. Our activity
Fig. 1 shows the timeline of our activities from 2010 to 2017. The di-
vision of pharmacology in National Institute of Health Sciences (NIHS)
has designed the timeline toward international acceptance of the pro-
posed methods using iPS-CMs according to the general validation pro-
cess as a lead laboratory.
Theﬁrst step of the validation studywas to survey the scientiﬁc basis
and regulatory needs of iPS-CMs for the safety pharmacology. Then, we
deﬁned the details for the methods such as experimental preparation,
methodology, calibration compounds, and endpoints to be measured,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. The timeline of our activities. The timeline of our activities from 2010 to 2017 shows key validation processes including test method deﬁnition, small-scale inter-laboratory test,
large-scale inter-laboratory test, international blinded test, and international acceptance. The reference to MHLW and AMED indicates sponsors in our research.
Fig. 2. Variations of action potential waveform from single iCell. Action potential
waveforms are obtained by patch-clamp techniques using iCell cardiomyocytes.
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method described in section 3was supported by a grant from theMinis-
try of Health, Labour, andWelfare (MHLW) from 2010 to 2011. The next
step of the validation studywas a small-scale initial inter-laboratory test
supported by a grant fromMHLW from2012 to 2014.We checked intra-
and inter-laboratory reproducibility and transferability at participating
laboratories. Then,we demonstrated that the testmethod can be reliable
in detecting the drug-induced repolarization delay and arrhythmias
with high reproducibility in inter-laboratory (Nakamura et al., 2014).
We presented the validation of protocol at ILSI-Health and Environ-
mental Sciences Institute (HESI) workshop on ‘Pluripotent Stem Cell:
Applications for Cardiovascular Risk Assessment’ held in March 2013.
We organized the ﬁrst think-tank meeting in Japan on non-clinical
and clinical cardiac safety assessment (Kirishima meeting, Jan 2014),
where Dr. Sager gave a presentation about Comprehensive in vitro
Proarrhythmia Assay (CiPA) activity with a special focus on a compre-
hensive assessment of multi ion channel effects (Chi, 2013; Colatsky
et al., 2016).
From our results of the initial inter-laboratory test and international
activities toward proarrhythmic risk assessment, the Japanese govern-
ment decided to support our validation study. A management team
for the validation study was organized to establish subgroups; we
included other participates from academia, industry and society. We
determined a minimum list of reference chemicals, optimized protocol
with a help of Japan Safety Pharmacology Society (JSPS), evaluated
relevance and reproducibility. We also checked transferability of the
protocol with JSPS and a consortium of Japan Pharmaceutical Manufac-
turers Association (JPMA Task force for iPS cells). To conduct the large-
scale validation study, NIHS organized a cpmsprtoim, Japan iPS Cardiac
Safety Assessment (JiCSA), as a task group with experts from academia,
industry, and government, supported by MLHW in Aug 2014 (http://
jicsa.org/en/). We have ﬁnalized the MEA-based protocol described in
section 4 with participating laboratories (Asakura et al., 2015). JiCSA
shared our standardized protocol with CiPA myocyte work stream. In
addition to our protocol, JiCSA shared the pilot study data using selec-
tive ion channel blockers (E-4031 for hERG, JNJ303 for IKs, mexiletine
for INa, and nifedipine for ICaL) and mixed channel blockers (ﬂecainide,
moxiﬂoxacin, ranolazine, and quinidine). We will describe the test
method deﬁnition and ‘points to consider’ to minimize the variability
of the protocol in details.
3. Test method deﬁnition
3.1. Type of cell preparation
There are some variations of action potential waveform from single
cell iPS-CM (Fig. 2), as previously reported (Zhang et al., 2009; Fatima
et al., 2011; Matsa et al., 2014). In the case of an embryoid-body cluster
and 3-dimensional model of CM, it was difﬁcult to perform experimentswith reproducible preparation in regarding to its size and cell density.
For these reasons, we selected a monolayer sheet as the type of cell
preparation.
3.2. Methodology, calibration compounds and endpoints to be measured
To evaluate the function of the monolayer sheet, there are several
protocols, such as MEA system, optical measurement system, motion
vector and propagation (Tanaka et al., 2009; Itzhaki et al., 2011;
Asakura et al., 2015; Ren et al., 2011; Kadota et al., 2013; Hayakawa et
al., 2014; Kitaguchi et al., 2016). MEA technology can easily provide ex-
tracellular FP duration (FPD) that is similar to QT duration of human
ECG. Based on these considerations, a small scale inter-laboratory test
evaluated the effects of E-4031 using iPS-CMs (iCell; Cellular Dynamics
International) and oneMEA platform (MED64; AlphaMed Scientiﬁc) at
multiple test sites (Nakamura et al., 2014).Wehave shown that FPD and
incidence of early afterdepolarization (EAD) or triggered activity (TA)
are which are reproducible and reliable endpoints at these sites under
our common protocol.
4. ‘Points to consider’ to minimize the variability of iCell/MEA assay
Before JiCSA started the large-scale inter-laboratory test using iCell
and one MEA platform (MED64), we listed ‘points to consider’ to mini-
mize the variability. Fig. 3 shows the workﬂow of the MEA assay using
iCell. To obtain reproducible and reliable data, there are many critical
parameters that may unexpectedly change during the experiment and
inﬂuence the electrical activity. Table 1 shows the factors thatmay affect
reproducibility and reliability of the MEA data. Details are below.
4.1. Cell density
We customized the cell number of themonolayer sheet on theMED
probe(Asakura et al., 2015), which is known to affect pharmacological
responses (Uesugi, Ojima, Taniguchi, Miyamoto, and Sawada, 2014).
When 15,000, 20,000, or 25,000 cells were plated on the MEA probe,
the number of electrodes that fulﬁlled the criteria (Fig. 4, ﬁrst peak am-
plitude ≥ ± 200 μV, second peak amplitude ≥15 μV) increased with
Fig. 3.WorkﬂowofMEA assay protocol. Experiment ofMEA is divided into three parts: 1) pre-plating onto 6-well culture plate; 2) Culturing ontoMEDprobe; 3) Recording. After thawing,
iPS-CMmedium were replaced every 2–3 days. Six-well culture plates and MED probe should be coated by 0.1% gelatin and 50 μg/ml ﬁbronectin, respectively. From day 10 to 14 post-
plating, FP activity can be recorded on the MEA system.
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ond peaks also increased as cell density increased. FPD corrected by
Fridericia's formula (FPDcF = FPD / [ISI / 1000]1/3) was comparable at
all three plating densities although beating rate signiﬁcantly decreased
at a plating density of 15,000 cells. Moreover, Cor.4U (AxioGenesis)
has approximately several times the cell size compared with iCell, and
the cell density should be optimized for drug assessment in each iPS-
CMs monolayer sheet on the MEA probe.
4.2. Coating of MEA probes
The surface properties of the cell dish arewell known to affect the at-
tachment and stability of CMs such as beat rate. JiCSA selected ﬁbronec-
tin as a coating reagent. Timing is also critical for ﬁbronectin coating.Fig. 4. Criteria of FP waveform. Criteria for baseline FP waveforms are shown: ﬁrst peak
amplitude ≥ ±200 μV, second peak amplitude ≥ 15 μV, inter-spike interval b 1715 ms,
and FPDcF ≥ 340 ms.
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PiCell attachmentworkswell as long as the added ﬁbronectin is not dried
up. Because the volume of the ﬁbronectin coating is just 2 μl, the well
will begin to dry within a minutes after aspiration of the excess ﬁbro-
nectin solution (about 1 μl). If the residual ﬁbronectin in thewell begins
to crystallize and turns white, the cardiomyocytes will not successfully
attach to the MEA probe.
4.3. Culture period
It is necessary to customize the culture time for evaluation of drugs
in iCell. The number of electrodes inMEA probewhich fulﬁlls the wave-
form criteria depended on culture time. Condition of the monolayer
sheet (such asmorphology), stability of parameters, and responsiveness
to drugs can be changed during long-term culture.
4.4. Measurement conditions (temperature, CO2 etc.)
It is well known that measurement temperature affects cardiac ion
channel activities (Hassinen, Paajanen, Haverinen, Eronen, and
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ture changes, even by airﬂow across the MEA, will quickly change the
beat rate and FPD. Since the probe volume is very small, heating may
not compensate such a change fast enough. Although MEA apparatus
has a heater plate that is located under the MEA probe, JiCSA recom-
mends the use of a digital validated thermometer to check a tempera-
ture in the MEA well at each sites. In addition to temperature, pH
should be stabilized by continuous perfusion with CO2 equilibrated cul-
ture medium (low rates, such as 0.1 ml/min) to obtain data.
4.5. High pass ﬁlter (HPF)
Analogue FP signals from the iCell monolayer sheets were acquired
through a 0.1-Hz HPF and a 3.5- to 10-kHz low-pass ﬁlter and digitized
at 20 kHz by using a MED64. We compared FP waveforms recorded
through 0.1-Hz and 1-Hz HPFs using the same preparation (Asakura
et al., 2015). Typical FP waveforms and action potential (AP)-like wave-
forms were observed when a 0.1-Hz HPF was used. As we have already
reported, the shape of the second peak can be inﬂuenced when the fre-
quency of the HPF was high (i.e., 1 Hz), because the second peak
contained the slow components of the current (Asakura et al., 2015;
Matsuo et al., 2015). JiCSA selected the 0.1 Hz HPF for the validation
study.
4.6. FP data analysis
As shown in Fig. 4, baseline FP waveforms with a sharp ﬁrst pos-
itive or negative deﬂection and a second positive deﬂection that
met the following criteria were used for analysis: ﬁrst peak ampli-
tude ≥ ± 200 μV, second peak amplitude ≥15 μV, inter-spike interval
(ISI) b 1715 ms, and FPDcF ≥340 ms (Asakura et al., 2015). Because
the MEA waveforms are different among the channels in a same
probe, we select a golden channel that fulﬁll the criteria and analyze
the effects of the drugs. After drugs were applied accumulatively,
JiCSA studies recorded FP waveforms for at least 10 min and the ISI
and FPDcF of the last 30waveforms at each experimental concentration
were averaged.
4.7. Incidence of EAD/TA
JiCSA and other groups have reported that drugs with TdP risks
prolonged FPD/FPDc and induced arrhythmogenic waveforms such
as early EAD and TA in the MEA assay using iPS/ES-CMs (Harris
et al., 2013; Nakamura et al., 2014; Kitaguchi et al., 2016; Clements
and Thomas, 2014). JiCSA deﬁned EAD as relatively slow negative
spikes appearing during the second positive deﬂection (repolariza-
tion phase). JiCSA deﬁned TA as one or more FP signals following
EAD with a sharp positive or negative deﬂection and an amplitude
≥ ± 100 μV.
4.8. Calibration compounds
There is some variation in cell sheet conditions including the attach-
ment to the electrode depending on the conductors. Selective ion chan-
nel blockers such as E-4031 can be used to assess the condition of
monolayer sheet and sensitivity of the test method in iCell.
5. Large-scale validation study
Following the establishment of our standardized MEA protocol,
JiCSA is now evaluating the effects of 60 compounds with different
TdP risk using iCell andMED64, supported by MHLW and Japan Agency
for Medical Research and development (AMED) from 2014 to 2017
(Fig. 1). All data will be included in a datamining systemwith the secu-
rity of information. A database is under construction for documenting
the drug approval process. An international blinded study organized aCiPA myocyte work stream is currently in progress. JiCSA and CiPA on-
going complementary studies would provide scientiﬁc evidence to ex-
plore proarrhythmic risk prediction using iPS-CMs. Our parallel efforts
will contribute to an international acceptance of a standardized test
method to assess the new cardiac safety paradigm (Colatsky et al.,
2016).
6. Feasibility of other iPS-CMs
6.1. Other cell type
Human iPS cells generated from a variety of cell types, which differ
in terms of tissue of origin, age, gender, race, availability, accessibility,
epigenetic status, reprogramming efﬁciency, mutational burden, and
cardiac differentiation protocols have improved dramatically
(Burridge, Keller, Gold, and Wu, 2012; Uosaki et al., 2011; Miki et al.,
2015). There are many iPS-CMs that are from academia and companies.
There are concerns about line-to-line and/or vendot-to-vendor differ-
ence It is important to get results of calibration compounds such as E-
4031. It might be interesting to compare the ECG data and FP of iPS-
CMs from the same origin. Collecting the iPS-CM data among healthy
donors might pave the way to personalized medicine and it might be
possible to predict an individual's sensitivity to drugs in the future.
6.2. Maturation
iPS-CMs are basically considered to exhibit typical biochemical and
electrophysiological characteristics of primary human CMs (Sinnecker,
Laugwitz, and Moretti, 2014). However, there are several differences
between iPS-CMs and adult CMs (Yang, Pabon, and Murry, 2014). For
example, most iPS-CMs display relatively depolarized maximum dia-
stolic membrane potentials (He, Ma, Lee, Thomson, and Kamp, 2003;
Honda, Kiyokawa, Tabo, and Inoue, 2011). In mature cardiomyocytes,
the large conductance of cardiac inward rectiﬁer K+ channels (IK1) is re-
sponsible for stabilizing resting membrane potentials. There is concern
about the low level expression of IK1 in iPS-CMs. In addition, iPS-CMs
have immature gene expression patterns and automaticity, which re-
ﬂects an immature state of cardiac differentiation (Synnergren,
Ameen, Jansson, and Sartipy, 2012). Development of mature iPS-CMs
is expected to provide more accurate clinical prediction.
7. Conclusion
This paper reviews our activities to validate a newmethod using iPS-
CMs andMEA system.Wehave summarized processes to deﬁne the test
method and ‘points to consider’ to minimize the variability. The ‘points
to consider’ shown here will provide critical information for establish-
ing the principals of good cell culture practice for using human iPS
cell-derived differentiated cells.
Our standardized protocol enables us to collect data successfully
with high reproducibility and reliability among laboratories. JiCSA has
already completed the collection of 60 compounds data and will evalu-
ate the predictability of the method for proarrhythmia risk. JiCSA and
CiPA collaboration would provide scientiﬁc evidences for international
acceptance of the new test method. Test methods using various types
of differentiated cells from human iPS cells would be developed to
bridge the gap between non-clinical tests and clinical trials and facilitate
3R as alternative testing methods. Thus, the standardized protocols
using iPS-CMs would realize a new paradigm for cardiac safety assess-
ment and contribute to human health.
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